 |
|
JAMA-EXPRESS
Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation
The CREATE Trial Group Investigators*
JAMA. 2005;293:427-435.
Context Although reperfusion therapy, aspirin,  -blockers, and angiotensin-converting enzyme inhibitors reduce mortality when used early in patients with acute myocardial infarction (MI), mortality and morbidity remain high. No antithrombotic or newer antiplatelet drug has been shown to reduce mortality in acute MI.
Objective To evaluate the effects of reviparin, a low-molecular-weight heparin, when initiated early and given for 7 days in addition to usual therapy on the primary composite outcome of death, myocardial reinfarction, or strokes at 7 and 30 days.
Design, Setting, and Patients A randomized, double-blind, placebo-controlled trial (Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation [CREATE]) of 15 570 patients with ST-segment elevation or new left bundle-branch block, presenting within 12 hours of symptom onset at 341 hospitals in India and China from July 2001 through July 2004.
Intervention Reviparin or placebo subcutaneously twice daily for 7 days.
Main Outcome Measure Primary composite outcome of death, myocardial reinfarction, or stroke at 7 and 30 days.
Results The primary composite outcome was significantly reduced from 854 (11.0%) of 7790 patients in the placebo group to 745 (9.6%) of 7780 in the reviparin group (hazard ratio [HR], 0.87; 95% CI, 0.79-0.96; P = .005). These benefits persisted at 30 days (1056 [13.6%] vs 921 [11.8%] patients; HR, 0.87; 95% CI, 0.79-0.95; P = .001) with significant reductions in 30-day mortality (877 [11.3%] vs 766 [9.8%]; HR, 0.87; 95% CI, 0.79-0.96; P = .005) and reinfarction (199 [2.6%] vs 154 [2.0%]; HR, 0.77; 95% CI, 0.62-0.95; P = .01), and no significant differences in strokes (64 [0.8%] vs 80 [1.0%]; P = .19). Reviparin treatment was significantly better when it was initiated very early after symptom onset at 7 days (<2 hours: HR, 0.70; 95% CI, 0.52-0.96; P = .03; 30/1000 events prevented; 2 to <4 hours: HR, 0.81; 95% CI, 0.67-0.98; P = .03; 21/1000 events prevented; 4 to <8 hours: HR, 0.85; 95% CI, 0.73-0.99; P = .05; 16/1000 events prevented; and  8 hours: HR, 1.06; 95% CI, 0.86-1.30; P = .58; P = .04 for trend). There was an increase in life-threatening bleeding at 7 days with reviparin and placebo (17 [0.2%] vs 7 [0.1%], respectively; P = .07), but the absolute excess was small (1 more per 1000) vs reductions in the primary outcome (18 fewer per 1000) or mortality (15 fewer per 1000).
Conclusions In patients with acute ST-segment elevation or new left bundle-branch block MI, reviparin reduces mortality and reinfarction, without a substantive increase in overall stroke rates. There is a small absolute excess of life-threatening bleeding but the benefits outweigh the risks.
*Authors/Writing Committee: Salim Yusuf, DPhil, Shamir R. Mehta, MD, MSc, Changchun Xie, PhD, Rashid J. Ahmed, BScH (Population Health Research Institute, Hamilton Health Sciences, and McMaster University, Hamilton, Ontario); Denis Xavier, MD, Prem Pais, MD (Institute of Population Health and Clinical Research, St John’s National Academy of Health Sciences, Bangalore, India); Jun Zhu, MD, Lisheng Liu, MD (Cardiovascular Institute and Fu Wai Hospital, Chinese Hypertension League Institute, Beijing, China).
RELATED LETTERS
Reviparin in Acute Myocardial Infarction
Francesco Buccelletti
JAMA. 2005;293(21):2595.
EXTRACT
| FULL TEXT
Reviparin in Acute Myocardial Infarction
Andrew T. Yan, Raymond T. Yan, and Shaun G. Goodman
JAMA. 2005;293(21):2595.
EXTRACT
| FULL TEXT
Reviparin in Acute Myocardial Infarction—Reply
Salim Yusuf, Chanchun Xie, and Janice Pogue
JAMA. 2005;293(21):2595-2596.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial
The CREATE-ECLA Trial Group Investigators*
JAMA. 2005;293(4):437-446.
ABSTRACT
| FULL TEXT
Simple Principles of Clinical Trials Remain Powerful
Robert M. Califf
JAMA. 2005;293(4):489-491.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
American College of Cardiology Foundation Task For et al.
J Am Coll Cardiol 2008;0:j.jacc.2008.08.002v1-14138.
FULL TEXT
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT
| FULL TEXT
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Goodman et al.
Chest 2008;133:708S-775S.
ABSTRACT
| FULL TEXT
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial
Peters et al.
Eur Heart J 2008;29:324-331.
ABSTRACT
| FULL TEXT
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment
Oldgren et al.
Eur Heart J 2008;29:315-323.
ABSTRACT
| FULL TEXT
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:210-247.
FULL TEXT
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:172-209.
FULL TEXT
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee
Antman et al.
Circulation 2008;117:296-329.
FULL TEXT
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
King et al.
Circulation 2008;117:261-295.
FULL TEXT
Enoxaparin and ST-elevation myocardial infarction: reply
Giraldez and Antman
Eur Heart J 2007;28:2952-2953.
FULL TEXT
Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction
Diaz et al.
JAMA 2007;298:2399-2405.
ABSTRACT
| FULL TEXT
Perspectives on the management of coronary artery disease in India
Karthikeyan et al.
Heart 2007;93:1334-1338.
ABSTRACT
| FULL TEXT
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
Murphy et al.
Eur Heart J 2007;28:2077-2086.
ABSTRACT
| FULL TEXT
Beyond Unfractionated Heparin and Warfarin: Current and Future Advances
Hirsh et al.
Circulation 2007;116:552-560.
FULL TEXT
Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis
Giraldez et al.
Eur Heart J 2007;28:1566-1573.
ABSTRACT
| FULL TEXT
Women, Acute Ischemic Heart Disease, and Antithrombotic Therapy: Challenges and Opportunities
Harrington
Circulation 2007;115:2796-2798.
FULL TEXT
Anticoagulants in heart disease: current status and perspectives
De Caterina et al.
Eur Heart J 2007;0:ehl492v1-34.
FULL TEXT
Update in cardiology.
Rapaport
ANN INTERN MED 2006;145:618-625.
FULL TEXT
Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease.
Coca et al.
JAMA 2006;296:1377-1384.
ABSTRACT
| FULL TEXT
Fondaparinux in ST-Segment Elevation Myocardial Infarction: The Drug, the Strategy, the Environment, or All of the Above?
Califf
JAMA 2006;295:1579-1580.
FULL TEXT
Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial
The OASIS-6 Trial Group*
JAMA 2006;295:1519-1530.
ABSTRACT
| FULL TEXT
Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials
Eikelboom et al.
Circulation 2005;112:3855-3867.
ABSTRACT
| FULL TEXT
Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit
Rothberg et al.
ANN INTERN MED 2005;143:241-250.
ABSTRACT
| FULL TEXT
Additional articles abstracted in ACP Journal Club
Evid. Based Med. 2005;10:126-126.
FULL TEXT
Rescuing COX-2 Inhibitors From the Waste Bin
Albini and Noonan
JNCI J Natl Cancer Inst 2005;97:859-860.
FULL TEXT
Reviparin in Acute Myocardial Infarction
Buccelletti
JAMA 2005;293:2595-2595.
FULL TEXT
Reviparin in Acute Myocardial Infarction
Yan et al.
JAMA 2005;293:2595-2595.
FULL TEXT
Does Reviparin Improve Outcomes in STEMI?
JWatch Emergency Med. 2005;2005:3-3.
FULL TEXT
LMWH Improves Post-STEMI Outcomes
Journal Watch Cardiology 2005;2005:1-1.
FULL TEXT
Low-Molecular-Weight Heparin After Myocardial Infarction
JWatch General 2005;2005:2-2.
FULL TEXT
Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial
The CREATE-ECLA Trial Group Investigators*
JAMA 2005;293:437-446.
ABSTRACT
| FULL TEXT
Simple Principles of Clinical Trials Remain Powerful
Califf
JAMA 2005;293:489-491.
FULL TEXT
|
